What have we learned from genome-wide association studies (GWAS) in Parkinson's disease?

doi:10.1016/j.arr.2022.101648

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

What have we learned from genome-wide association studies (GWAS) in Parkinson's disease?

Ageing research reviews - 1 Aug 2022

Fernández-Santiago Rubén, Sharma Manu

Abstract excerpt

After fifteen years of genome-wide association studies (GWAS) in Parkinson's disease (PD), what have we learned? Addressing this question will help catalogue the progress made towards elucidating disease mechanisms, improving the clinical utility of the identified loci, and envisioning how we can harness the strides to develop translational GWAS strategies. Here we review the advances of PD GWAS made to date...

Topics

Genetic Predisposition to Disease
Genome-Wide Association Study
Humans
Learning
Parkinson Disease

Source

Open in PubMed

Identifiers

PMID: 35595184
DOI: 10.1016/j.arr.2022.101648

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics